GILEAD SCIENCES SL

Nurix Therapeutics announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia patients in the second half of 2025, including both accelerated approval and confirmatory Phase 3 studies.

Cartography Biosciences secured $67 million in Series B funding led by Pfizer Ventures to advance its lead T-cell engager CBI-1214 targeting colorectal cancer into Phase 1 trials.

Health Hope Pharma and Hanmi Pharm have granted Gilead Sciences exclusive global licensing rights to encequidar, a first-in-class P-glycoprotein inhibitor, specifically for virology applications.

Lupin Limited has received tentative FDA approval for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, targeting a significant HIV treatment market.

The XBI biotech index experienced significant gains following regulatory developments and corporate announcements in the biotechnology sector.

Gilead Sciences has broken ground on a new 180,000 square foot Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City headquarters as part of a $32 billion U.S. investment through 2030.

Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025, following strong first half 2025 financial results.

I-Mab appointed three seasoned biotech executives to key leadership positions, including Dr. Robert Lenz and Ms. Xin Liu to the Board of Directors and Dr. Ken Takeshita to the Scientific Advisory Board.

Kite, a Gilead Company, has entered into a definitive agreement to acquire Interius BioTherapeutics for $350 million to advance in vivo CAR-T cell therapy development.

CVS Health, the largest U.S. pharmacy benefit manager, will not add Gilead's new HIV prevention drug Yeztugo to its commercial plans, citing clinical, financial, and regulatory factors despite the drug's proven 99.9% effectiveness.